The China Securities Regulatory Commission (CSRC) issued a notice on April 3 regarding supplementary information requirements for overseas listing filings. Shenzhen Salubris Pharmaceuticals Co.,Ltd. (002294.SZ) was asked to provide further details on the proportion of funds raised intended for use domestically versus overseas. The regulator also inquired whether the company plans to repatriate any funds to mainland China, the specific proportion involved, and if the capital allocation involves any overseas investment projects. Furthermore, the CSRC requested confirmation that all necessary approvals, verifications, and filing procedures from relevant authorities have been completed.
According to a listing application submitted to the Hong Kong Stock Exchange on February 12, Shenzhen Salubris Pharmaceuticals is pursuing an initial public offering in Hong Kong. Goldman Sachs, Citigroup, and CITIC Securities are acting as joint sponsors for the offering.
Simultaneously, the CSRC has required the company to detail the establishment and changes in share capital and shareholders during its period as a limited liability company, in accordance with applicable regulatory guidelines. It must also explain the specific regulatory procedures fulfilled for establishing overseas subsidiaries, including those related to outbound investment and foreign exchange registration, and provide a conclusive opinion on compliance.
According to its prospectus, the company is a pioneer in the treatment of cardiovascular-renal-metabolic diseases in China. Data from Frost & Sullivan indicates that in 2024, it was the second largest pharmaceutical company in China's cardiovascular innovative drug market by revenue. As of the latest practicable date (February 4, 2026), the company possessed the second largest pipeline of innovative drugs for cardio-renal-metabolic syndrome among domestic enterprises by scale.
The company's portfolio includes six innovative drugs: Xinnitan (approved in 2013), Fulitan (approved in 2024), Xinliting (approved in 2024), Xinchatuo (approved in 2025), Fulian (approved in 2025), and Ennaluo (initially approved in early 2023, with an expanded indication approved in 2025).
Comments